COVID-19 Saliva-based Screening Market is likely to register double digit 2.4% CAGR during 2026
COVID-19 Saliva-based Screening Market is likely to register double digit 2.4% CAGR during 2026 – 2031
Stay updated with breaking news from Chembio Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
COVID-19 Saliva-based Screening Market is likely to register double digit 2.4% CAGR during 2026 – 2031
Global Point-of-Care (POC) Diagnostic Market to be Driven by Rising Prevalence of Diseases in the Forecast Period of 2021-2026
Key Prominent Players Covered in the Infectious Disease Point of Care Diagnostics Market Research Report Are F. Hoffmann-La Roche Ltd (Basel, Switzerland)...
/PRNewswire/ -- According to the latest report, "HIV Diagnostics Market by Test Type (Antibody Test, Viral Load Test, CD4 Test), End-use (Diagnostic...
Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil HAUPPAUGE, N.Y., July 20, 2021 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 to support the urgent needs of Brazil’s Ministry of Health in addressing the COVID-19 pandemic. The DPP SARS-CoV-2 Antigen test is desig...